Santen Pharmaceutical (OTCMKTS:SNPHY) Shares Gap Up – Still a Buy?

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY)’s share price gapped up prior to trading on Wednesday . The stock had previously closed at $10.34, but opened at $11.5380. Santen Pharmaceutical shares last traded at $11.5380, with a volume of 354 shares changing hands.

Analyst Upgrades and Downgrades

Separately, Zacks Research upgraded Santen Pharmaceutical to a “hold” rating in a research report on Monday, April 13th. One analyst has rated the stock with a Hold rating, According to MarketBeat.com, the company presently has a consensus rating of “Hold”.

Santen Pharmaceutical Trading Up 10.3%

The business’s 50 day moving average price is $10.86 and its two-hundred day moving average price is $10.69. The stock has a market cap of $3.68 billion and a P/E ratio of 0.10.

Santen Pharmaceutical Company Profile

Santen Pharmaceutical Co, Ltd. is a Japan‐based specialty pharmaceutical company focused exclusively on ophthalmology. Headquartered in Osaka, Santen engages in the research, development, manufacture and marketing of prescription and over‐the‐counter products for the diagnosis and treatment of eye diseases. Its core product portfolio includes therapies for glaucoma, dry eye, retinal disorders, uveitis and post‐operative care, as well as surgical equipment and diagnostic agents designed to support comprehensive eye care.

With roots tracing back to the late 19th century, Santen has grown from a domestic manufacturer to a global ophthalmic specialist.